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Cholecystokinin-2 receptors (CCK2R) are overexpressed in a variety of malignant diseases and therefore have gained certain
attention for peptide receptor radionuclide imaging. Among extensive approaches to improve pharmacokinetics and metabolic
stability of minigastrin (MG) based radioligands, the concept of multivalency for enhanced tumour targeting has not been
investigated extensively. We therefore utilized fusarinine C (FSC) as chelating scaffold for novel mono-, di-, and trimeric
bioconjugates for targeting CCK2R expression. FSC-based imaging probes were radiolabelled with positron emitting radionuclides
(gallium-68 and zirconium-89) and characterized in vitro (log𝐷, IC50, and cell uptake) and in vivo (metabolic stability in BALB/c
mice, biodistribution profile, and microPET/CT imaging in A431-CCK2R/A431-mock tumour xenografted BALB/c nude mice).
Improved targeting did not fully correlate with the grade ofmultimerization.The divalent probe showed higher receptor affinity and
increased CCK2R mediated cell uptake while the trimer remained comparable to the monomer. In vivo biodistribution studies 1 h
after administration of the 68Ga-labelled radioligands confirmed this trend, but imaging at late time point (24 h) with 89Zr-labelled
counterparts showed a clearly enhanced imaging contrast of the trimeric probe compared to the mono- and dimer. Furthermore,
in vivo stability studies showed a higher metabolic stability for multimeric probes compared to the monomeric bioconjugate. In
summary, we could show that FSC can be utilized as suitable scaffold for novel mono- and multivalent imaging probes for CCK2R-
related malignancies with partly improved targeting properties for multivalent conjugates. The increased tumour accumulation of
the trimer 24 h postinjection (p.i.) can be explained by slower clearance and increased metabolic stability of multimeric conjugates.
1. Introduction
Receptor targetingwith radiolabelled peptides has become an
emerging field in nuclear medicine for early diagnosis and
therapy of cancerous diseases [1, 2]. The overexpression of
cholecystokinin receptor subtype 2 (CCK2R) is involved in
various malignancies, such as medullary thyroid carcinoma
(MTC), small cell lung cancer (SCLC), and neuroendocrine
tumours (NET) [3, 4] and therefore represents an interest-
ing target for peptide receptor radionuclide imaging and
therapy. In a preclinical study, different derivatives based
on human minigastrin (H2N-Leu-(Glu)5-Ala-Tyr-Gly-Trp-
Met-Asp-Phe-NH2) for targeting CCK2R expression were
investigated in order to find the ideal targeting sequence [5].
This study reported that four C-terminal amino acids (-Trp-
Met-Asp-Phe-NH2) are mandatory for selectivity and high
affinity towards CCK2R. Different variations are allowed in
theN-terminal region to improve in vivo targeting properties
and pharmacokinetics, especially kidney uptake which is
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closely related to the appearance of negatively charged amino
acids. Based on this knowledge a variety of MG derivatives
have been synthesized by different groups with the aim of
reducing kidney but retaining tumour uptake [6]. Further
studies have shown that thesemodifications are unfortunately
accompanied by low metabolic stability predominantly for
MG11 [7, 8]. In vivo stability is a major issue for imaging
of receptor expression with small peptide-based molecules.
Rapid degradation may lead to decreased tumour uptake and
low imaging contrast. Several attempts have been made to
overcome this issue, for example, coinjection of the neutral
endopeptidase inhibitor phosphoramidon [9]with promising
results. Less effort has been spent on a different approach:
the design of multivalent constructs. This could increase
the probability of receptor target interaction and therefore
increase receptor avidity [10, 11] as well as promoting the
formation of metabolites able to rebind to the receptor. By
this, increased apparent stability tumour uptake and therefore
improved imaging contrast would be achieved as has been
proposed by Carlucci and coworkers [12]. Sosabowski and
coworkers were, to the best of our knowledge, the only
group so far reporting on a divalent probe (MGD5) for
nuclear imaging of CCK2R expression.This tracer consisting
of the bifunctional chelator (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid, DOTA) conjugated to a MG deriva-
tive crosslinked via thiol-maleimide to a second sequence
of the peptide was radiolabelled with indium-111 for single
photon emission tomography (SPECT). It showed increased
affinity and tumour uptake compared to itsmonomeric coun-
terpart 111In-APH070 [13]. Our group recently reported on
fusarinine C (FSC), a cyclic siderophore based bifunctional
chelator, providing a scaffold for site-specific conjugation
of up to three targeting vectors with excellent complexing
properties towards the PET radionuclides gallium-68 and
zirconium-89 [14, 15]. As positron emission tomography
(PET) provides higher resolution compared to SPECT we
initiated this study to compare novel mono-, di-, and trimeric
FSC-conjugates for targeting CCK2R expression. Due to
low metabolic stability minigastrin analogue (MG11) was
chosen as model peptide and was conjugated via thiol-
maleimide crosslink as shown in Scheme 1. The resulting
mono- and multimeric conjugates were radiolabelled with
gallium-68 and zirconium-89 followed by in vitro and in vivo
characterization.
2. Experimental Section
2.1. Analytical [Radio]-RP-HPLC. Reversed-phase (RP) high-
performance liquid chromatography (HPLC) analysis was
carried out using the following instrumentation: Ulti-
Mate 3000 RS UHPLC pump, UltiMate 3000 autosam-
pler, UltiMate 3000 column compartment (25∘C oven
temperature), UltiMate 3000 Variable Wavelength Detec-
tor (Dionex, Germering, Germany; UV detection at 𝜆
= 220 nm), radio-detector (Gabi Star, Raytest; Strauben-
hardt, Germany), Jupiter 5 𝜇m C18 300 A˚ 150 × 4.6mm
(Phenomenex Ltd. Aschaffenburg, Germany) column with
acetonitrile (ACN)/H2O/0.1% trifluoroacetic acid (TFA) as
mobile phase; flow rate of 1mL/min; gradient: 0.0–3.0min 0%
ACN, 3.0–5.0min 0–30% ACN, 5.0–20.0min 30–60% ACN,
20.0–25.0min 60–80% ACN.
2.2. Preparative RP-HPLC. Sample purification via RP-HPLC
was performed on a Gilson 322 Pumpwith a Gilson UV/VIS-
155 detector (UV detection at 𝜆 = 220 nm) using a PrepFC
automatic fraction collector (Gilson, Middleton, WI, USA).
Following ACN/H2O/0.1% TFA multistep gradients were
used on a Eurosil Bioselect Vertex Plus 30 × 8mm 5 𝜇m
C18A 300 A˚ precolumn and Eurosil Bioselect Vertex Plus
300 × 8mm 5𝜇m C18A 300 A˚ column (Knauer, Berlin, Ger-
many) and a flow rate of 2mL/min: gradient A: 0.0–1.0min
10% ACN, 1.0–25.0min 10–50% ACN, 25.0–28.0min 50%
ACN, 28.0–30.0min 10% ACN; gradient B: 0.0–1.0min 20%
ACN, 1.0–26.0min 20–60% ACN, 26.0–28.0min 60% ACN,
28.0–30.0min 60–20% ACN; gradient C: 0.0–1.0min 20%
ACN, 1.0–26.0min 20–80% ACN, 26.0–28.0min 80% ACN,
28.0–30.0min 20% CAN.
2.3. MALDI-TOF MS. Matrix-assisted laser desorption/ion-
ization time-of-flight mass spectrometry was performed on
a Bruker microflex bench-top MALDI-TOF MS (Bruker
Daltonics, Bremen, Germany). Samples were prepared on a
microscout target (MSP96 target ground steel BC, Bruker
Daltonics) using dried-droplet method and 𝛼-cyano-4-
hydroxycinnamic acid (HCCA, Sigma-Aldrich, Handels
GmbH, Vienna, Austria) as matrix. All spectra were recorded
by summarizing 800 laser shots per spot and FlexAnalysis 2.4
software was used for data processing.
2.4. Radio-ITLC. Instant thin layer chromatography (ITLC)
analysis was performed using TLC-SG strips (Varian, Lake
Forest, CA, USA) and 0.1M sodium citrate solution (pH 5)
for 68Ga-conjugates and 0.05M EDTA solution (pH 7) for
89Zr-conjugates as mobile phase. The strips were analyzed
using a TLC scanner (Scan-RAM, LabLogistic, Sheffield,
UK). Radiolabelled bioconjugates remained at the start (𝑅𝑓 =
< 0.1) while free radionuclidesmigratedwith the solvent front
(𝑅𝑓 = > 0.9).
2.5. Gamma Counter. A 2480 Automatic Gamma Counter
Wizard2 3󸀠󸀠 (Perkin Elmer, Waltham, MA, USA) was used to
measure the radioactivity of samples retrieved from in vitro
and in vivo experiments.
2.6. Cell Culture. The human epidermoid carcinoma cell line
(A431) stably transfected with the plasmid pCR3.1 containing
the full coding sequence for the human CCK2R (A431-
CCK2R) and with the empty vector alone (A431-mock) was
a kind gift from Aloj [16]. Both cell lines were maintained
at 37∘C in a humidified atmosphere of 95% air/5% carbon
dioxide in tissue culture flasks (Cellstar; Greiner Bio-One,
Kremsmunster, Austria) using Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% v/v fetal bovine
serum (FBS) and 1% v/v penicillin-streptomycin-glutamine
(PSG) solution media (Gibco, Invitrogen Corporation, Pais-
ley, UK).
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Scheme 1: Route of synthesis for novel mono- and multimeric MG conjugates (stereochemistry omitted).
2.7. Precursor Preparation. The synthesis of mono- and mul-
tivalent FSC-based minigastrin derivatives is presented in
detail in the supplementary materials sections.
2.8. Radiochemistry
2.8.1. Radiolabelling with Gallium-68. Fractionated elution
of a commercially available 68Ga/68Ge-generator (IGG100,
Eckert &Ziegler Isotope Products, Berlin, Germany; nominal
activity of 1850MBq) with 0.1M hydrochloric acid (HCl,
Rotem Industries, Israel) was used to obtain 68GaCl3 (gallium
chloride, ∼310MBq) in 1mL eluate. For labelling 20 𝜇g
(5–10 nmol) of conjugate (mono-, di-, or trimer) was mixed
with 100–500𝜇L eluate (∼30–160MBq) and the pH was
adjusted to 4.5 by adding 20𝜇L of sodium acetate solu-
tion (1.14M) per 100 𝜇L eluate. The mixture was incubated
for 5–15min at RT and then analyzed by radio-ITLC and
radio-RP-HPLC. Following this procedure but using a 100-
fold molar excess of GaBr3 (gallium bromide) dissolved in
0.1 NHCl instead of generator eluate gave the natGa-chelated
peptides which were used for binding affinity measure-
ments.
2.8.2. Radiolabelling with Zirconium-89. The cyclotron pro-
duced radionuclide was purchased from PerkinElmer
(Waltham, US) and delivered as 89Zr-oxalic acid solution
(1M and ∼1MBq/𝜇L). Approximately 10MBq (10 𝜇L)
was neutralized with 9.6𝜇L sodium carbonate solution
(1M) at RT. After 3min 100 𝜇L of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (0.5M, pH
6.98) was mixed with the radionuclide solution followed
by addition of the corresponding peptide (20𝜇g) and the
mixture was incubated for 30–60min at ambient temper-
ature. The reaction was monitored by radio-ITLC. In case of
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animal experiments 20𝜇L of CaCl2 (calcium chloride) was
added to precipitate CaC2O4 (calcium oxalate). The resulting
suspension was centrifuged for 5min at 14 × 103 rpm
(Eppendorf Centrifuge 5424, Hamburg, Germany) and an
aliquot from the supernatant was further diluted in PBS
for in vivo evaluation. Representative chromatograms are
shown in the Supplementary Materials (Figure S1).
2.9. In Vitro Characterization
2.9.1. Stability Study. To assess the stability of the radionu-
clide complex the radiolabelled peptides were diluted with
PBS to a concentration of 5 𝜇M. Aliquots of 50 𝜇L were
mixed with PBS (as control), human serum, and a 1.000-fold
molar excess over radioligand of either EDTA (pH 7), DTPA
(pH 7), or FeCl3 (pH 5). Then samples were incubated in
duplicate at 37∘C up to 4 h for gallium-68 and up to 7 days
for zirconium-89 labelled peptides. Samples were analyzed
at selected time points via radio-RP-HPLC for 68Ga-labelled
probes and radio-ITLC for 89Zr-labelled peptides. The ITLC
strips were cut into half and measured in the gamma counter
to determine the percentage of labelled peptide (origin) to
free radionuclide (solvent front).
2.9.2. Distribution Coefficient (log𝐷). Aliquots (50 𝜇L) of
68Ga- and 89Zr-labelled mono-, di-, and trimer (10 𝜇M)
were diluted in 450𝜇L PBS. After adding 500𝜇L octanol
the mixture was vortexed with 1400 rpm (MS 3 basic vor-
texer, IKA, Staufen, Germany) for 15min at RT followed by
centrifugation for 2min at 4500 rpm. Subsequently, 100 𝜇L
aliquots of the organic and the aqueous layer were collected
and log𝐷 values were calculated using Excel (𝑛 = 3, six
replicates) after gamma counter measurement.
2.9.3. Protein Binding. For protein binding measurement
68Ga- and 89Zr-labelled peptides were incubated in PBS as
control and fresh human serumand samplesweremaintained
at 37∘C. After 1, 2, and 4 h aliquots (25 𝜇L) were analyzed
by size exclusion chromatography using MicroSpin G-50
columns (Sephadex G-50, GE Healthcare, Vienna, Austria)
according to manufacturer’s protocol. The samples were
measured in the gamma counter and the percentage between
protein-bound (eluate) and free conjugate (column) was
calculated.
2.9.4. Whole Cell Receptor Binding Affinity Studies (IC50).
A431-CCK2R cells were diluted to a density of 5× 106 cells/mL
in 50mM HEPES buffer (pH 7.3) containing 5mMMgCl2
(magnesium chloride) and 0.3% bovine serum albumin
(BSA). MultiScreen Filter Plates HTS (96-wells, 1 𝜇m glass
fiber filter, Merck Millipore, Darmstadt, Germany) were
washed twice with 200𝜇L of 10mM TRIS-buffered saline
(pH 7.3) and 100 𝜇L of cell suspension was added to each
well. Hereafter cells were incubated in triplicate with increas-
ing concentrations [0.001−1.000 nM] of competitor solution
(50 𝜇L of metal-bound ([natGa]) mono-, di-, and trimer as
well as DOTA- MG11 as reference diluted in 20mM HEPES,
10mMMgCl2 and 0.1% BSA). After 10min incubation at RT
50 𝜇L of radioligand (human 125I-[Leu15]-Gastrin I, 4.5 ×
104 cpm, prepared as previously published [17]) was added
and the plate was maintained under shaking conditions
(Compact Shaker KS-15 control, 200/min) for 1 h. Thereafter
eachwell waswashed twicewith 200 𝜇LTRIS-buffered saline.
Then the filters were measured in the gamma counter and
IC50 values were calculated by using nonlinear curve fitting
withOrigin 6.1 software (Northampton,MA,USA) according
to the following formula: [NS + SB/(1 + 𝑥/IC50)].
2.9.5. CCK-2 Receptor Internalization Assay. Determination
of the receptor-mediated radioligand uptake inA431- CCK2R
cells was conducted as previously published [17]. Briefly,
2 × 106 cells were seeded per well (12-well plates, Nunc,
Thermo Scientific) and left to grow over night. After washing
twice and adjusting the volume to 1.2mL with DMEM
containing 1% FBS, 150 𝜇L blocking solution (100-fold molar
excess of pentagastrin in PBS/0.5% BSA solution) was added
to one-half while 150 𝜇L PBS/0.5% BSA was added to the
other half of wells for volume compensation. Hereafter,
150 𝜇L of the radiolabelled conjugate (diluted in PBS/0.5%
BSA, approximately 30.000 cpm) was added to have a final
concentration of approximately 1 nM in the assay and the
plates were incubated at 37∘C. After 1 h, 2 h, and 4 h (in case
of zirconium-89) the cells were washedwith ice-coldmedium
(=wash fraction), with ice-cold 0.05M glycine buffer (pH
2.8) (membrane bound fraction) and finally lysed with 2M
sodium hydroxide (internalized fraction). All fractions were
measured in the gamma counter to determine the percentage
of cell associated radioactivity in relation to total activity
added.
2.10. In Vivo Characterization. All animal experiments were
conducted in compliance with the Austrian and Dutch
animal protection laws and with approval of the Austrian
Ministry of Science (BMWF-66.011/000604-II/3b/2012 and
BMWFW-66.011/0049-WF/II/3b/2014). In vivo stability stud-
ies were conducted in 5-week-old female BALB/c mice (in-
house breed, ZVTA Innsbruck, Dr. Hermann Dietrich).
The biodistribution studies were performed using female
8−10-week-old athymic BALB/c nude mice (Charles River
Laboratories, Sulzfeld, Germany). Tumour xenografts were
induced by subcutaneous injection of 2 × 106 A431-CCK2R
cells (receptor positive) in the right and the same amount
of A431-mock (receptor negative) in the left flank. Tumours
were allowed to grow until they had reached a volume of
0.3–0.6 cm3.
2.10.1. InVivo Stability. 68Ga-labelled conjugateswere injected
via a lateral tail vein using an amount of 1.5 nmol and a
radioactivity of 15MBq. After 5min mice were euthanized
by cervical dislocation and blood samples were taken by
heart puncture. Aliquots of the blood were immediately
precipitated by adding 0.1% TFA/ACN (1 : 1 v/v) and the
supernatant was diluted withH2O and analyzed by radio-RP-
HPLC.
2.10.2. Ex Vivo Biodistribution. To evaluate the biodistribu-
tion profile nude mice (𝑛 = 4) were intravenously injected
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with either 1-2MBq 68Ga- or 0.3MBq 89Zr-labelled mono-,
di-, and trimer (0.1–0.2 nmol).The animals were sacrificed by
cervical dislocation after 1 h as well as 2 h and 4 h in case of
68Ga- and 89Zr-labelled trimer, followed by the collection of
organs and tissue.The collected samplesweremeasured in the
gamma counter and the results were calculated as percentage
of injected dose per gram tissue (% ID/g).
2.10.3. MicroPET/CT Imaging. Small animal imaging exper-
iments were carried out with an Inveon microPET/CT
scanner (Siemens Preclinical Solutions, Knoxville, USA).
A group of eight double tumour xenografted mice were
injected intravenously with either 8–13MBq of 68Ga-labelled
tracers (0.2–0.5 nmol) or 3–5MBq of 89Zr-labelled peptides
(0.4–1.0 nmol). MicroPET images were acquired under gen-
eral anaesthesia (isoflurane/O2) for 15–60min with static
PET/CT scans after 1 h and additionally after 4 and 24 h
for 89Zr-labelled conjugates. The microPET/CT scans were
reconstructed with OSEM3D-SPMAP (PET, matrix size 256
× 256) and Feldkamp (CT, Shepp Logan filter).
2.11. Statistical Analysis. Statistical analysis was performed
using the Student’s 𝑡-test with 𝑃 value < 0.05 indicating
significance.
3. Results
3.1. Precursor Synthesis. MG11-SH could be obtained in good
yield following SPPS protocol. [Fe]FSC could be extracted
from fungal culture in sufficient purity to be used for further
modification without additional purification. Acetylation
reaction resulted in a mixture of mono- and multiple acety-
lated derivatives of [Fe]FSC due to three identical primary
amines but the desired products were easily accessible via
preparative RP-HPLC purification. Functionalization with
maleimide linker was straightforward utilizing a NHS-ester
strategy and conjugation of up to three targeting vectors
was conducted site-specifically via maleimide-thiol crosslink
reaction. All intermediates as well as final conjugates were
obtained in good yield, with excellent chemical purity (>95%;
analytical RP-HPLC, UV absorption at 𝜆 = 220 nm), and
corresponding mass analysis was in good agreement with the
calculated values.
3.2. Radiolabelling. Mono- and multimeric conjugates were
quantitatively labelled with gallium-68 after 5–15min and
after 30–60min with zirconium-89 at high molar activities
and used without further purification.
3.3. In Vitro Characterization. The complex stability was
evaluated by incubating the radiolabelled conjugates in 1000-
fold molar excess of EDTA, DTPA, FeCl3 (iron chloride),
fresh human serum, and PBS over a period of 4 h for gallium-
68 and 7 days for zirconium-89, respectively. The radiola-
belled peptides showed no significant release of radionuclide
in all media except EDTA after 7 d where 20 to 30% release
of radionuclide was observed indicating excellent stability of
68Ga and 89Zr-FSC. The data from this transchelation study
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Figure 1: Binding affinity (IC50 values) of metal-bound (
natGa)
mono-, di-, and trimer on whole A431-CCK2R cells.
are presented in detail in the Supplementary Materials (Table
S1).
Distribution coefficient (log𝐷) values and protein bind-
ing data are summarized in Table 1. The results indicate
a hydrophilic character of all conjugates but, as expected,
clearly showed that the grade of multimerization is accompa-
nied by increased lipophilicity. Binding to serumproteinswas
low (<10%) for monomeric, moderate (10–25%) for dimeric,
and high for (30–50%) trimeric conjugates. Furthermore,
protein binding was consistent over time for 68Ga-labelled
mono- and dimer but increased for 68Ga-trimer whereas all
89Zr-labelled counterparts showed a slight increase over a
period of 4 h.
Competition assays on whole A431-CCK2R (Figure 1)
revealed high binding affinity as the IC50 values were in
the low nanomolar range for all bioconjugates. The affinity
of the dimer (0.85 ± 0.15 nM) was approximately 10-fold
higher while the monomer (9.7 ± 3.5 nM) and the trimer
(8.3 ± 2.2 nM) remained comparable to the reference peptide
DOTA-MG11 (9.5 ± 0.5 nM) [17].
Cellular processing of A431-CCK2R cells incubated with
68Ga- and 89Zr-labelled mono- and multimeric tracers is
summarized in Figure 2. In general, all conjugates showed
increasing uptake over time while the unspecific cell bound
fraction of corresponding blocking studies remained <1%,
thus indicating highly specific receptor-mediated cell uptake.
Furthermore the 68Ga-dimer showed significantly increased
uptake after 1 h-incubation compared to the monomer (𝑃 =
9.01 × 10−6) and the trimer (𝑃 = 0.009) while after 2 h-
incubation only the uptake of the monomer remained lower
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Table 1: Distribution coefficient and protein binding of mono- and multimeric conjugates radiolabelled with gallium-68 and zirconium-89.
68Ga-labelled 89Zr-labelled
Monomer Dimer Trimer Monomer Dimer Trimer
Distribution
coefficient
log𝐷
(pH 7.4) −2.99 ± 0.02 −2.38 ± 0.04 −2.20 ± 0.07 −3.17 ± 0.06 −2.83 ± 0.02 −2.41 ± 0.04
Protein binding
(%)
1 h 3.71 ± 0.86 15.94 ± 1.25 40.69 ± 0.93 5.51 ± 0.41 15.86 ± 0.31 31.52 ± 0.19
2 h 4.16 ± 0.22 18.77 ± 2.93 44.33 ± 1.41 6.48 ± 0.45 20.83 ± 0.15 35.73 ± 0.92
4 h 3.16 ± 0.49 17.86 ± 0.32 48.32 ± 1.71 7.28 ± 0.40 26.75 ± 0.49 41.39 ± 2.81
Data are presented as mean ± SD (𝑛 = 3).
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Figure 2: Cell-uptake studies of A431-CCK2R cells incubated with 68Ga-labelled mono- and multimers (a) and 89Zr-labelled counterparts
(b). Blocking was performed with pentagastrin in 100-fold molar excess over the conjugate.
(𝑃 = 0.001). This trend was observed in the same manner for
the 89Zr-labelled counterparts and was substantiated by the
results after 4 h of incubation.
3.4. In Vivo Characterization. Investigations on the in vivo
stability are shown in Figure 3. RP-HPLC analysis of the
corresponding blood samples showed increasing amount of
intact radioligand to be found in following order trimer >
dimer >monomer, indicating that multimerization is accom-
panied with increased metabolic stability. The results of the
ex vivo biodistribution studies in double tumour xenografted
nude mice are summarized in Table 2 and corresponding
tumour-to-organ ratios are presented in Table 3. Mono-
and dimeric bioconjugates radiolabelled with gallium-68
were rapidly cleared from the bloodstream and showed
highly specific tumour targeting properties as the uptake in
nontargeted tissue was very low, except kidneys, 1 h after
administration of the radiotracers. Furthermore, the dimer
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Figure 4: Three-dimensional volume projections of fused microPET/CT static images in A431-CCK2R [Tu (+)] and A431-mock [Tu (−)]
tumour xenograft-bearing BALB/c nude mice 1 and 2 h p.i. of the 68Ga-labelled conjugates. [Ki: kidneys]
showed significantly (𝑃 < 0.005) increased tumour uptake
compared to the monomer but also higher accumulation in
renal tissue. However, the corresponding tumour-to-organ
ratios revealed no significant difference inmost of the organs.
In contrast, the 68Ga-trimer cleared slowly from the body and
showedhigher blood level 1 h p.i.Thiswas substantiated as the
uptake in malignant tissue was comparable to the monomer
1 h p.i. but increased consistently over time accompanied by
very high accumulation renal tissue. In addition, also an
elevated accumulation in nontargeted tissue was observed for
the 68Ga-trimer, resulting in significantly lower tumour-to-
organ ratios compared to mono- and dimer. In comparison,
the respective 89Zr-labelled counterparts showed a similar
behaviour in vivo with somewhat lower tumour uptake 1 h
p.i. but consistently higher accumulation in renal tissue. 89Zr
mono- and dimers revealed a trend towards reduced tumour-
to-organ ratios as compared to the 68Ga-counterparts. In
contrast, over time the 89Zr-trimer showed a faster elimi-
nation from blood and lower unspecific tissue uptake. This
resulted in higher tumour-to-organ ratios compared to the
68Ga-labelled counterpart especially 4 h p.i. and may be
attributed to the increased hydrophilic character of this
radiotracer. Small animal PET/CT imaging studies confirmed
these findings and the results for 68Ga-labelled conjugates
are presented in Figure 4 whereas imaging of the 89Zr-
labelled counterparts is shown in Figure 5. The predominant
accumulation of radioactivity found in the kidneys, related
to elimination via renal pathway accompanied by tubular
reabsorption, was in good agreement with the results of our
biodistribution studies and clearly showed that kidney uptake
is increased with the grade of multimerization. Furthermore,
imaging showed highly specific targeting properties for all
conjugates as CCK2 related malignancies were clearly visu-
alized already 1 h after injection without major differences
between the bioconjugates. However, imaging at 2 h p.i. for
68Ga-labelled and that at 24 h p.i for 89Zr-labelled trivalent
probe pronounce the increased uptake in CCK2R expressing
tissue.
4. Discussion
The cyclic siderophore based chelator FSC enables a straight-
forward multistep synthesis of multivalent imaging probes.
Three amines attached to the chelating scaffold of FSC can
be utilized for further modifications whereas DOTA, for
example, offers only one binding site for conjugation of
targeting probes.This results in a different but more symmet-
rical architecture of FSC-related multivalent bioconjugates.
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Figure 5: Animal imaging studies of 89Zr-labelled conjugates in
A431-CCK2R/A431-mock tumour xenografted BALB/C nude mice;
3D volume rendered projections of fused static microPET/CT
images.
Asymmetric tracer design might not be critical in case of
small peptides for targeted imaging but can become an
issue in case of multimerization of larger biomolecules (e.g.,
engineered scaffold proteins, ESP) as the asymmetry can
result in less flexibility or increased sterically hindrance at
the target interaction site. The suitability for FSC as chelating
scaffold for ESP has recently been shown although acetyla-
tion of two amines was conducted to design a monovalent
affibody construct [18]. Furthermore, FSC can be labelled
with gallium-68 and zirconium-89 at RT with sufficient
complex stability (Table S1), which is beneficial in case of
heat-sensitive molecules.This is also of particular interest for
CCK2R targeting peptide derivatives containing methionine
as previous studies have shown that heating related oxidation
is accompanied by reduced receptor affinity [19]. In contrast,
DOTA-conjugates have to be heated for efficient radiola-
belling with gallium-68 and in case of oxidation sensitivity of
the targeting probe additives (e.g., ascorbic acid) are needed
to improve radiochemical purity. Both 68Ga and 89Zr FSC-
conjugates showed high in vivo stability; there was also no
significant difference in bone uptake between 68Ga and 89Zr
counterparts, indicating insignificant in vivo release of 89Zr,
confirming recent findings [15].
Overall FSC-based imaging probes showed high CCK2R
binding affinity (Figure 1) with values in the low nanomo-
lar range. The divalent probe showing higher affinity is
quite consistent with previous reports on 111In-MGD5 [11].
Interestingly, increasing the valency from mono- to trimeric
constructs, no increase in binding affinity was achieved.
All FSC-based conjugates showed highly specific receptor
targeting as demonstrated in vitro (Figure 2) and also in
vivo imaging (Figures 4 and 5) confirmed these findings.
Multimerization is accompanied by decreased hydrophilicity
and increased binding to serum proteins (Table 2) leading
to slower pharmacokinetics in vivo, especially for the trimer.
Furthermore, kidney retentionwas considerably increased by
the grade of multimerization (Table 3). This is substantiated
by the faster blood clearance of 89Zr-labelled counterparts
due to higher hydrophilicity but increased kidney uptake
which may be related to the additional charge introduced
as the hexadentate chelator FSC only compensates three of
four positive charges of Zr4+. Overall, high kidney retention
might be critical in case of therapeutic use but is tolerable for
diagnostic applications of radiopharmaceuticals [20].
Interestingly, improvement due to multimerization was
more pronounced at later time points. While internalization
data revealed higher cell uptake at 1 h for the dimer over
the trimer, at later time points the trimer showed higher
internalization rates. This phenomenon was also seen in vivo
where the dimer revealed a higher tumour uptake at 1 h p.i.,
whereas the uptake increased substantially after 2 and 4 h
p.i for the trimer exceeding the values of the dimer at 1 h.
p.i.. This in vivo effects may be explained by a slower target
accumulation of the trimer but also by the higher protein
binding and slow blood clearance that may act as depot to
prolong the tracer concentration at the tumour site, improv-
ing imaging contrast over time (Table 3). Furthermore, the
improved metabolic stability (Figure 3) of multimeric radi-
oligands targeting CCK2R expression, which has been shown
in this study for the first time, also may result in the
formation of rebinding metabolites enhancing the imaging
contrast over time. This hypothesis is substantiated by the
slow tumour washout particularly observed for 89Zr-trimer
at 24 h p.i (Figure 5) making imaging at late timepoints with
multivalent peptides tracers radiolabelled with zirconium-89
not per se uninteresting. Additionally, improving metabolic
stability by this multivalency-approach might also be highly
interesting for non-radiopharmaceutical-based applications
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such as therapeutic peptides but definitely warrants further
investigations regarding formation of metabolites and their
target interaction ability.
5. Conclusion
In this study, novel mono- and multimeric bioconjugates uti-
lizing FSC for radiolabelling with gallium-68 and zirconium-
89 for PET applications targeting CCK2R expression were
synthesized and evaluated for the first time. The resulting
imaging probes showed highly specific receptor targeting
characteristics which were only partly improved in terms
of binding affinity and in vivo targeting by the grade of
multimerization. However, the higher metabolic stability and
improved target retention in vivo of multivalent conjugates
warrant further investigations on the formation of metabo-
lites with the retained receptor binding ability. Overall this
study established FSC as a promising scaffold for the devel-
opment of mono- and multimeric targeted bioconjugates for
molecular imaging with PET.
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Supplementary Materials
This section contains a detailed description regarding the
synthesis of the conjugates. Furthermore representative RP-
HPLC chromatograms of 68Ga-labelled as well as radio-ITLC
analysis of 89Zr-labelled probes are shown in Figure S1. The
results of transchelation studies for 68Ga- and 89Zr-labelled
conjugates are presented in Table S1. Figure S1: (A) radio-
RP-HPLC chromatograms of 68Ga- and (B) radio-ITLC
analysis of 89Zr-labelled mono- and multimeric conjugates.
Table S1: transchelation studies of 68Ga and 89Zr mono- and
multimers; data is expressed as percentage of peptide-
associated radioactivity. (Supplementary Materials)
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